Administration and Mgmt (California)

行政和管理（加利福尼亚州）

• 批准号: 8120933
• 负责人: HUGH ROSEN
• 金额: $ 211.22万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8120933
• 关键词: Area; Attention; Biological Assay; Budgets; California; Chemistry; Consultations; Goals; Head; Informatics; Lead; Metric; Monitor; Resolution; Screening procedure; Therapeutic; Time; United States National Institutes of Health; assay development; base; experience; meetings

D8.2 Administration and Management: The TSRI Center will be administered by the PI in consultation with the Center Screening Committee. The functional cores (Assay Implementation, uHTS Implementation, Informatics, PK, Chemistry and QA) will meet on a monthly basis to set goals and metrics towards those interim goals, as well as monitor progress towards the global Specific Aims with their timed milestones. Variances of > 1 Quarter from the planned global milestones will be flagged by the PI and brought to the attention of the CSC. Remedial steps will be taken in real time to solve the specific problems. Should the PI, in consultation with the CSC, identify variances that, after remedial steps have been taken, still impact on scope or timeliness of deliverables, the PI will draw this to the attention of NIH staff where appropriate and seek guidance. In addition to the successful implementation ahead of time and on budget of the MLSCN Center and chairing the MLSCN Steering Group, the PI had significant therapeutic area head level industrial experience at Merck. It is well within his capabilities to define key Center problems and lead them to resolution at the appropriate level within the Center or the NIH Project Team. Integration of Assay Development, Adaptation and uHTS implementation is managed by the monthly meeting of the Screening Coordination Committee (SCC).

D8.2行政和管理：TSRI中心将由PI与 中心筛选委员会。功能核心(Assay实现，uHTS实现， 信息学、PK、化学和QA)将每月开会，为这些部门设定目标和衡量标准 监测中期目标，并监测在实现全球具体目标方面取得的进展及其规定的里程碑。 第一季度与计划的全球里程碑的差异将由PI标记并提交给 中国证监会请注意。将实时采取补救措施，以解决具体问题。是否应该让PI，in 与CSC协商，确定在采取补救措施后对范围仍有影响的差异 或交付成果的及时性，PI将在适当时提请NIH工作人员注意这一点，并寻求 指导。除了提前和在预算内成功实施MLSCN中心和 作为MLSCN指导小组的主席，PI在以下领域拥有重要的治疗领域负责人级别的行业经验 默克公司。他完全有能力定义关键中心的问题，并在 中心或NIH项目组的适当级别。化验分析的发展、适应和整合 UHTS的实施由筛查协调委员会(SCC)的月会管理。